Back

Bisdemethoxycurcumin mitigates Alzheimer disease pathology through autophagy-mediated reduction of senescence and amyloid beta

Khajuria, P.; Kour, D.; Sharma, K.; Singh, L.; Banoo, R.; Manhas, D.; P, R.; Nandi, U.; Bharate, S.; Ahmed, Z.; Kumar, A.

2025-05-23 pharmacology and toxicology
10.1101/2025.05.19.654834 bioRxiv
Show abstract

AD pathology is accompanied by increased senescence and reduced levels of autophagy in the brain. We investigated whether pharmacologically inducing autophagy could alter the senescent phenotype and help ameliorate AD pathology. We discovered that Bisdemethoxycurcumin (BDMC), a natural compound found in Curcuma longa, stimulates autophagy in primary astrocytes. We found that autophagy and senescence exhibit an inverse relationship in aging astrocytes, with increased expression of senescent proteins and downregulation of autophagic proteins. However, treatment of aged astrocytes with BDMC reversed the senescent phenotype by ameliorating the impaired autophagy. Interestingly, the senescent phenotype persisted when autophagy was downregulated by knockdown of AMPK. Additionally, BDMC-induced autophagy aided in the removal of amyloid beta that was administered externally to the astrocytes. Further, to validate these results in a mouse model of AD, we confirmed that BDMC can significantly penetrate the blood-brain barrier (BBB) in mice. Therefore, we administered 50 and 100 mg/kg b.w. of BDMC to transgenic 3xTg-AD mice for two months. In their hippocampus, the Control 3xTg-AD animals showed more senescent cells and lower autophagy levels. In contrast, autophagic proteins were significantly upregulated while senescence indicators, such as senescence-associated secretory phenotype (SASP) proteins, were sharply downregulated in the brain of treated animals. Additionally, we discovered that the treated mices hippocampus had a significantly lower amyloid beta load. These molecular changes in the brain were ultimately reflected in the improved working memory and neuromuscular coordination behavior of mice treated with BDMC. This study warrants further evaluation of BDMC for the management of AD. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=139 SRC="FIGDIR/small/654834v1_ufig1.gif" ALT="Figure 1"> View larger version (53K): org.highwire.dtl.DTLVardef@1176bbforg.highwire.dtl.DTLVardef@a2e2cdorg.highwire.dtl.DTLVardef@1d824f5org.highwire.dtl.DTLVardef@1628a30_HPS_FORMAT_FIGEXP M_FIG This illustration was created by using biorender.com C_FIG

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Alzheimer's Research & Therapy
52 papers in training set
Top 0.1%
40.6%
2
The Journal of Prevention of Alzheimer's Disease
10 papers in training set
Top 0.1%
7.0%
3
npj Aging
15 papers in training set
Top 0.2%
4.1%
50% of probability mass above
4
Aging Cell
144 papers in training set
Top 1%
4.1%
5
PLOS ONE
4510 papers in training set
Top 38%
3.7%
6
ACS Chemical Neuroscience
60 papers in training set
Top 0.7%
3.0%
7
Frontiers in Pharmacology
100 papers in training set
Top 1%
2.8%
8
International Journal of Molecular Sciences
453 papers in training set
Top 6%
1.9%
9
Pharmaceuticals
33 papers in training set
Top 0.6%
1.7%
10
Scientific Reports
3102 papers in training set
Top 56%
1.7%
11
Science of The Total Environment
179 papers in training set
Top 4%
1.4%
12
eLife
5422 papers in training set
Top 46%
1.4%
13
Journal of Medicinal Chemistry
68 papers in training set
Top 0.8%
1.3%
14
International Journal of Biological Macromolecules
65 papers in training set
Top 3%
1.0%
15
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.6%
1.0%
16
Life Sciences
25 papers in training set
Top 1%
0.9%
17
Alzheimer's & Dementia
143 papers in training set
Top 2%
0.9%
18
Aging
69 papers in training set
Top 2%
0.9%
19
ACS Omega
90 papers in training set
Top 3%
0.8%
20
European Journal of Neuroscience
168 papers in training set
Top 1%
0.8%
21
Experimental Neurology
57 papers in training set
Top 1%
0.8%
22
Biomedicine & Pharmacotherapy
43 papers in training set
Top 1%
0.8%
23
Journal of Neuroinflammation
50 papers in training set
Top 0.9%
0.8%
24
NAR Molecular Medicine
18 papers in training set
Top 0.2%
0.8%
25
Metabolomics
11 papers in training set
Top 0.4%
0.8%
26
Molecules
37 papers in training set
Top 2%
0.7%
27
Biomedicines
66 papers in training set
Top 4%
0.7%
28
Neurotherapeutics
11 papers in training set
Top 0.7%
0.5%